After Acadia's presented detailed results from its Phase 3 HARMONY study at the Clinical Trials on Alzheimer's Disease Meeting, Piper Jaffray analyst Danielle Brill said "the data looked great on all key metrics" and she called the presentation "a clear win." Given that she thinks the lead in phase response rates are supportive of pimavanserin's efficacy for active psychosis and the safety data looked "very clean," Brill continues to think that the FDA will be supportive of pimavanserin label expansion for the dementia-related psychosis, or DRP, indication, she tells investors. Brill reiterates an Overweight rating on Acadia shares.